Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

6.88
+0.06500.95%
Volume:65.47K
Turnover:440.32K
Market Cap:66.58M
PE:-1.33
High:7.10
Open:6.80
Low:6.52
Close:6.81
52wk High:29.98
52wk Low:5.31
Shares:9.68M
Float Shares:7.38M
Volume Ratio:0.85
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1698
EPS(LYR):0.0175
ROE:-121.87%
ROA:-38.88%
PB:2.51
PE(LYR):392.79

Loading ...

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

GlobeNewswire
·
Yesterday

Seres Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 23

Seres Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $12

THOMSON REUTERS
·
Jun 23

Seres Therapeutics announces two transactions

TIPRANKS
·
Jun 05

Seres Therapeutics Reshapes Finances with Lease Restructuring

TIPRANKS
·
Jun 05

BRIEF-Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027

Reuters
·
Jun 05

Seres Therapeutics amends Vowst deal, secures USD 25 million milestone buyout from Nestlé Health Science

Reuters
·
Jun 05

Seres Therapeutics - Restructures Lease to Reduce Annual Facility Cash Costs and Long-Term Lease Liability

THOMSON REUTERS
·
Jun 05

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce on-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

THOMSON REUTERS
·
Jun 05

Seres Therapeutics - NestlÉ Health Science to Pay Seres $25 Mln in 2026 for Vowst Milestone Buy-Out

THOMSON REUTERS
·
Jun 05

Seres Therapeutics director Hans-Juergen Woerle resigns from board

Reuters
·
Jun 02

Seres Therapeutics presents at H.C. Wainwright BioConnect investor conference

Reuters
·
May 12

Seres Therapeutics (MCRB) Gets a Buy from Canaccord Genuity

TIPRANKS
·
May 06

Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

Benzinga
·
May 05

Seres Q1 FY26 net loss turns to USD 19.9 million; revenue at USD 358,000

Reuters
·
May 05

BRIEF-Seres Therapeutics Q1 EPS USD -2.08

Reuters
·
May 05

Seres Therapeutics Inc: as of March 31, 2026, Seres Had $29.8 Mln in Cash and Cash Equivalents,Expects to Fund Operations Through Q3 of 2026

THOMSON REUTERS
·
May 05

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

GlobeNewswire
·
May 04

Seres Therapeutics Inc expected to post a loss of $1.88 a share - Earnings Preview

Reuters
·
May 01

Seres Therapeutics announces three presentations at 2026 ESCMID congress

TIPRANKS
·
Apr 20